T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to extend life for elderly lymphoma patients
Disease control OngoingThis study looks at whether adding an oral drug (CC-486) to standard chemotherapy (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas live longer without their cancer returning. About 422 participants will receive either the standard tr…
Matched conditions: T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 01:49 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests whether adding the drug acalabrutinib to a CAR-T cell therapy (lisocabtagene maraleucel) can improve outcomes for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. About 28 adults will receive the combination, and resea…
Matched conditions: T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC